Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1
(WorldNews Denmark)

Company Announcement Based on a recent planned review, the Data Monitoring Committee (DMC) recommends Phase Ib/II study of daratumumab plus atezolizumab (anti PD-L1 antibody) in patients with previously treated non-small cell lung cancer to be terminated. Phase I MMY2036 study of daratumumab plus JNJ-63723283 (anti PD-1 antibody) in patients with multiple myeloma, discontinued Health Authorities have been informed about these events and Janssen has contacted its partner companies conducting daratumumab and anti-PD-(L)1 combination studies to discuss ceasing enrollment and dosing of the combination while the data is being further investigated Copenhagen, Denmark; May 26, 2018 - Genmab A/S...